Abstract
The $^{99m}$Tc radiolabeling method using the NHS-MAG3 chelator has been successfully applied to duplex siRNA, enabling the noninvasive visualization of siRNA delivery in vivo. This approach preserves the biological activity of the siRNA while providing high-sensitivity imaging capabilities.
Introduction
RNA interference (RNAi) represents a transformative frontier in gene therapy, offering the ability to selectively silence disease-causing genes. However, the clinical translation of siRNA is hindered by the challenge of monitoring delivery to target tissues in real-time. Traditional tracking methods, such as optical imaging, often lack the necessary penetration depth for clinical use. This study addresses this gap by developing a stable, noninvasive method to track duplex siRNA using Technetium-99m ($^{99m}$Tc) and SPECT/scintigraphy.
Methods
The researchers targeted hTERT (human telomerase reverse transcriptase), a protein highly expressed in most cancers. To ensure stability, the siRNA was modified with uniform 2'-O-methyl (2'-OMe) groups.
The antisense (guide) strand was conjugated with NHS-MAG3 (S-acetyl N-hydroxysuccinimide-mercaptoacetyltriglycine) under mild conditions to preserve the RNA's delicate structure. This conjugate was then radiolabeled with $^{99m}$Tc. The team evaluated the probe's stability in human serum and its biological potency in HepG2 cells before conducting in vivo biodistribution and imaging studies in tumor-bearing mice.
Key Results
Stability and Labeling Efficiency
The radiolabeling process was highly efficient, reaching 73.4% with a specific activity of 25.9 GBq/mmol. Crucially, the duplex siRNA demonstrated superior stability compared to single-stranded versions. In human serum, the radiolabeled duplex maintained over 94% purity for up to 6 hours at both room temperature and 37°C.
Biological Potency
A critical requirement for any tracking label is that it must not interfere with the drug's function. RT-PCR and Western blot analyses confirmed that the $^{99m}$Tc-labeled siRNA remained biologically active. It achieved an average inhibitory rate of 76.7% on hTERT protein expression, a performance nearly identical to that of unlabeled siRNA.
In Vivo Visualization
Scintigraphy provided clear visualization of tumor xenografts as early as 30 minutes post-injection. The targeted siRNA showed significantly higher accumulation in tumors compared to scrambled control siRNA, indicating active genetic targeting rather than simple passive accumulation via the EPR effect. At 6 hours, the tumor-to-blood ratio for the targeted probe was 2.62, and the tumor-to-muscle ratio was 6.02.
Discussion and Limitations
While the $^{99m}$Tc-MAG3-siRNA platform successfully visualized tumor delivery, the study noted high accumulation in the kidneys and liver. This "abdominal clutter" is common for small radiolabeled molecules and may obscure tumors in those regions or pose renal toxicity risks at higher therapeutic doses.
Despite these challenges, the study proves that labeling the antisense strand of a modified duplex siRNA is a viable strategy for real-time tracking. This method could serve as a powerful companion diagnostic tool for evaluating the efficacy of RNA-based therapeutics in clinical trials, allowing researchers to quantitatively verify that the genetic "payload" has reached its destination.
Summary updated